The biotech trade mission to India led by Ventura County marks a significant step in connecting US based life science organizations with one of the world’s fastest growing biotechnology markets. Led by Ventura County Supervisor Jeff Gorell and organized by Brent Reinke, Founder of the BioScience Alliance, the mission was supported by the US Commercial Service and the Economic Development Collaborative. With stops in New Delhi, Bengaluru, and Hyderabad, the delegation engaged directly with key players across India’s pharmaceutical, medical device, and regenerative medicine sectors.
For FOMAT, participation in this biotech trade mission to India aligned directly with the organization’s commitment to expanding the reach of inclusive clinical research and building international partnerships that advance healthcare delivery for diverse populations.
Why the biotech trade mission to India matters for clinical research
India’s biotechnology sector has grown rapidly in recent years, driven by a large and diverse patient population, a strong pharmaceutical manufacturing base, and increasing government investment in research and development infrastructure. For US based clinical research organizations, India represents both a source of potential partnership and a model for community based healthcare engagement at scale.
The mission’s strategic focus on New Delhi, Bengaluru, and Hyderabad reflected the geographic concentration of India’s biotech leadership. Each city brought different strengths to the table, including regulatory expertise, pharmaceutical production capacity, and technology driven innovation, giving the Ventura County delegation a comprehensive view of the opportunities available for collaboration.
FOMAT’s role in the delegation
Nicholas Focil, CEO of FOMAT, represented the organization as part of the Ventura County delegation. His participation reflected FOMAT’s commitment to global engagement and its recognition that the future of clinical research depends on building relationships across borders and across communities.
Through his interactions with Indian biotech leaders, Focil explored potential partnerships that align with FOMAT’s core mission: making clinical research more accessible to underserved and diverse populations. India’s demographic diversity and the scale of its unmet healthcare needs make it a natural partner for an organization whose research model is built around inclusion, community trust, and broad population reach.
FOMAT’s diversity in clinical trials capabilities are designed precisely for the kind of cross cultural engagement that this biotech trade mission to India made possible. Inclusive recruitment practices, bilingual research teams, and community based investigator networks are tools that translate across geographies.
Key engagements during the biotech trade mission to India
The delegation participated in three roundtable conferences with industry stakeholders focused on trade regulations, research and development partnerships, and investment opportunities. These sessions provided direct insight into India’s biotech regulatory environment and the practical pathways available for US companies seeking to establish collaborative agreements.
The delegation also met with US Ambassador Eric Garcetti to discuss the regulatory challenges and opportunities facing US life science companies operating in or partnering with Indian organizations. The conversation addressed both the barriers to entry and the growing interest among Indian companies in expanding into the US market, a dynamic that creates natural opportunities for organizations like FOMAT with established US infrastructure and a national research network.
Site visits to Biocon Limited and Dr. Reddy’s Laboratories, two of India’s largest and most globally recognized biotech firms, allowed the delegation to explore specific collaboration opportunities in cancer research and pharmaceutical development. Both firms are recognized by the US FDA as manufacturers meeting international regulatory standards. These visits underscored the complementary strengths that exist between Ventura County’s innovation capabilities and India’s pharmaceutical production expertise.
The delegation also engaged with leaders from the Biotechnology Industry Research Assistance Council, known as BIRAC, which serves as the innovation arm of India’s Department of Biotechnology. This interaction provided valuable context for understanding how government supported biotech research operates in India and where joint development opportunities might be most viable.
Connecting Ventura County biotech to a global network
The mission positioned Ventura County as a hub for biotechnology innovation and a credible destination for foreign investment in life sciences. For the organizations that participated, including FOMAT, the relationships formed with Indian biotech executives, venture capitalists, and research and development specialists represent a foundation for future collaboration that could produce meaningful advances in healthcare.
The Economic Development Collaborative played a central coordination role throughout the mission, ensuring that participating companies were well prepared to engage with the Indian market and could make the most of each interaction. This organizational support allowed FOMAT and other delegates to focus on substantive conversations about partnership potential rather than logistics.
For clinical research specifically, the biotech trade mission to India opened a dialogue about how community based research models developed in the US context might inform approaches to clinical trial access in India’s diverse and geographically distributed population. The parallels between underserved communities in the US and underserved communities in India create a shared language for organizations committed to inclusive research.
What comes next for FOMAT and global biotech collaboration
The connections established through this mission are the beginning rather than the conclusion of an international engagement strategy. As Ventura County’s biotech sector continues to grow and seek new markets, FOMAT’s participation positions the organization at the intersection of domestic research excellence and global partnership development.
For sponsors and CROs evaluating research partners with both domestic capability and international perspective, FOMAT’s Phase I through Phase IV clinical research capabilities provide a proven operational foundation. Our patient recruitment excellence and national investigator network reflect the same commitment to reach, diversity, and quality that drove FOMAT’s engagement in this biotech trade mission to India.
The future of clinical research is increasingly global. The partnerships that begin in conversations between delegates and biotech leaders ultimately serve patients across the United States and around the world.